Microbot Medical Inc (NASDAQ:MBOT) major shareholder Alliance Investment Management acquired 24,873 shares of Microbot Medical stock in a transaction dated Thursday, November 21st. The stock was purchased at an average cost of $2.21 per share, with a total value of $54,969.33. Following the completion of the purchase, the insider now owns 302,720 shares of the company’s stock, valued at $669,011.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Alliance Investment Management also recently made the following trade(s):

  • On Tuesday, November 26th, Alliance Investment Management acquired 37,986 shares of Microbot Medical stock. The stock was purchased at an average cost of $1.95 per share, with a total value of $74,072.70.
  • On Tuesday, November 19th, Alliance Investment Management acquired 2,400 shares of Microbot Medical stock. The stock was purchased at an average cost of $3.00 per share, with a total value of $7,200.00.
  • On Monday, January 14th, Alliance Investment Management acquired 1,773 shares of Microbot Medical stock. The stock was purchased at an average cost of $6.44 per share, with a total value of $11,418.12.
  • On Wednesday, January 9th, Alliance Investment Management acquired 14,280 shares of Microbot Medical stock. The stock was purchased at an average cost of $2.19 per share, with a total value of $31,273.20.
  • On Wednesday, January 16th, Alliance Investment Management acquired 102,309 shares of Microbot Medical stock. The stock was purchased at an average cost of $3.70 per share, with a total value of $378,543.30.

MBOT opened at $8.60 on Friday. Microbot Medical Inc has a fifty-two week low of $1.38 and a fifty-two week high of $19.40.

Microbot Medical (NASDAQ:MBOT) last posted its earnings results on Wednesday, November 14th. The biotechnology company reported ($0.58) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.02.

A number of analysts have recently issued reports on MBOT shares. ValuEngine raised shares of Microbot Medical from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Zacks Investment Research cut shares of Microbot Medical from a “hold” rating to a “sell” rating in a research note on Saturday, September 22nd. Finally, LADENBURG THALM/SH SH cut shares of Microbot Medical from a “buy” rating to a “hold” rating and set a $1.75 target price for the company. in a research note on Monday, November 19th. They noted that the move was a valuation call.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://theolympiareport.com/2019/01/20/insider-buying-microbot-medical-inc-mbot-major-shareholder-acquires-24873-shares-of-stock.html.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.

Featured Article: How is inflation measured?

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.